ArticleBMC geriatrics2025
Renal function affects the plasma concentration and hematological toxicity of linezolid in elderly patients: a propensity-matched cohort analysis.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Therapeutic Drug Monitoring and Pharmacokinetic Researches of Oxazolidinone Antibacterial Agents in the Elderly Patients.Clinical interventions in aging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundThe relationships of renal function with linezolid trough concentration (Cmin) and hematological toxicity have not been clarified in elderly patients.
methodsIn this propensity-matched cohort analysis, elderly patients receiving linezolid at four tertiary hospitals in Beijing between May 2021 and March 2024 were included. The patients were grouped by renal function and propensity score matching (PSM) was used to balance baseline characteristics. Linezolid Cmin and hematological indices were monitored dynamically.
resultsAmong 320 patients, 152 were eventually enrolled after PSM, including 56 (36.8%) patients with normal renal function (RN) and 96 (63.2%) patients with renal dysfunction (RD). Cmin at 3–5 (12.5 mg/L vs. 21.2 mg/L, P = 0.001) and 6–10 days (14.8 mg/L vs. 27.4 mg/L, P < 0001) was significantly lower in the RN group. The risk of linezolid-associated thrombocytopenia (LAT) and linezolid-associated anemia (LAA) in the RD group was 4.485 folds and 2.308 folds higher than in the RN group. The decreases in hematological indices were significantly higher in RD group than in RN group.
conclusionsRenal function significantly affected linezolid Cmin and hematological toxicity, and the dose of linezolid should be reduced in elderly patients with renal dysfunction.
trial registrationChiCTR2100045707; Registration Date: 23/04/2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.